Clinical trialNCT03326063CompletedPhase 2Interventional

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

SponsorBrigham and Women's HospitalEnrollment38Aspirin-Sensitive Asthma With Nasal PolypsAspirin-exacerbated Respiratory DiseaseAsthma, Aspirin-InducedNasal Polyps

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elliot Israel, MD
Brigham and Women's Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Asthma Research Center, Brigham and Women'S Hospital
Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IfetrobanPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Apr 2018
Primary completion: 30 Mar 2022
Completion: 15 Apr 2023
Last update posted: 14 Jul 2023
Registered enrollment: 38
Registry id: NCT03326063

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.